UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 21, 2005
INVITROGEN CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 0-25317 | 33-0373077 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 1600 Faraday Avenue, Carlsbad, CA | 92008 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (760) 603-7200
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 1 - Registrant’s Business and Operations
Item 1.01 Entry into a Material Definitive Agreement
Chief Executive Officer Compensation. On April 21, 2005, at a meeting of the Compensation and Organization Committee of the Board of Directors of the Company (the “Committee”), the Committee approved an increase in the base salary of Mr. Gregory T. Lucier, the Company’s Chief Executive Officer. Specifically, effective as of April 25, 2005, Mr. Lucier’s new base salary was set by the Committee at $875,000. The Committee also approved a lump sum cash bonus, in the amount of $23,077, to be paid to Mr. Lucier, which represents the unpaid increase in base salary from January 1, 2005 through April 25, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Invitrogen Corporation | ||||
| (Registrant) | ||||
| Date April 25, 2005 | ||||
/s/ David F. Hoffmeister | ||||
David F. Hoffmeister Sr. Vice President, Chief Financial Officer | ||||